| Date | Subject | Details |
|---|---|---|
| 2024/12/20 | Medigen and Oncolys Sign an Amendmentregarding Sales of OBP-301 | 20241220 |
| 2024/12/19 | The progress update of the new drug underdevelopment, OBP-301 | 20241219 |
| 2024/12/14 | Taiwan MOHW has approved a New Version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Taichung Tzu Chi Hospital | 20241214 |
| 2024/10/28 | Announcement of the date of the board ofdirectors meeting for the third quarter of 2024financial report | 20241028 |
| 2024/10/14 | Taiwan MOHW has approved a New Version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Taichung VGH | 20241014 |
| 2024/09/16 | The Company Has Obtained an Approval from TFDAto Conduct a Phase I/II Clinical Trial using AllogeneicNK Cells | 20240916 |
| 2024/08/30 | Announcement on Behalf of the Subsidiary, TBGDiagnostics Ltd of the election result of directorsof company | 20240830-2 |
| 2024/08/30 | Announcement on Behalf of the Subsidiary, TBGDiagnostics Ltd of the Resolutions of theShareholders’ Meeting | 20240830-1 |
| 2024/08/09 | Announcement of board meeting approved the consolidated financial statements 2024Q2 | 20240809-2 |
| 2024/08/09 | Announcement for the change of Company’s Accounting Officer | 20240809-1 |
| 2024/08/06 | Announcement on Behalf of the Subsidiary, TBGDiagnostics Ltd of the 2024 Annaul General Meeting | 20240806-2 |
| 2024/08/06 | Complete Enrollment of PI-initiated Phase IClinical Trial for OBP-301-Chemoradiation CombinationTherapy in the U.S. | 20240806-1 |
| 2024/08/05 | Announcement of the date of the board of directors meeting for the second quarter of 2024 financial report | 20240805 |
| 2024/07/04 | Taiwan MOHW has approved the collaborativeautologous Gamma-Delta T cell therapy project bythe Company and TaipeiMunicipal Wanfang Hospital | 20240704 |
| 2024/06/06 | Taiwan MOHW has approved a New Version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Wanfang Hospital | 20240606 |
| 2024/06/03 | The first participant has been enrolled in the investigator-initiated Phase II clinical trial of the new drug OBP-301 in the United States. | 20240603 |
| 2024/05/28 | Announcement of the Members of the Company’ssixth term of Remuneration Committee | 20240528-6 |
| 2024/05/28 | Announcement of the Members of the Company’ssecond term of Audit Committee | 20240528-5 |
| 2024/05/28 | Announcement of the Election of the Chairmanof the Board of Directors | 20240528-4 |
| 2024/05/28 | Approval of the Proposal to Lift the Non-CompeteRestrictions on Newly Appointed Directors at 2024Shareholders’ Meeting. | 20240528-3 |
| 2024/05/28 | Announcement of the Newly Elected Board of Directors(including Independent Directors) at the 2024 AnnualShareholders’ Meeting of the Company | 20240528-2 |
| 2024/05/28 | Announcement of Important Resolutions fromthe 2024 Shareholders’ Meeting of the Company | 20240528-1 |
| 2024/05/10 | The Company’s 2024Q1 consolidated financial statements have been approved by the Board of Directors | 20240510 |
| 2024/05/02 | Announcement of the date of the board ofdirectors meeting for the first quarter of 2024financial report | 20240502 |
| 2024/04/23 | Taiwan MOHW has approved a new version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Hualien Tzu Chi Hospital | 20240423 |
| 2024/04/10 | Announcement Completion of Cancellation of NewlyIssued Restricted Employee Shares and Relevant Changesin Registration | 20240410 |
| 2024/03/29 | The Ministry of Health and Welfare has approvedthe collaborative autologous Gamma-Delta T cell therapyproject by the Company and Chi Mei Hospital, Liouying | 20240329 |
| 2024/03/26 | Taiwan MOHW has approved a new version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Changhua Christian Hospital | 20240326 |
| 2024/03/20 | Taiwan MOHW has approved a New Version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Chi Mei Hospital, Liouying | 20240320 |
| 2024/03/12 | Announcement to explain the difference between thecompany’s consolidated monthly operating incomedeclaration for 12/2024 and accountants audited numbers. | 20240312 |
| 2024/03/11 | Announcement to explain the difference between thecompany’s consolidated monthly operating incomedeclaration for 12/2024 and accountants audited numbers. | 20240311-6 |
| 2024/03/11 | The Board of Directors has resolved not to distributedividends | 20240311-5 |
| 2024/03/11 | The Company’s board of directors resolvedto convene 2024 General Shareholder’s meeting | 20240311-4 |
| 2024/03/11 | Appointment of our company’s new ChiefScientific Officer | 20240311-3 |
| 2024/03/11 | The Company’s Board of Directors has resolvedto redeem and cancel the restricted stocks issued toemployees | 20240311-2 |
| 2024/03/11 | The Company’s 2023 consolidated financialstatements have been approved by the Board of Directors | 20240311-1 |
| 2024/02/29 | Our company has applied to the Taiwan Food and DrugAdministration (TFDA) for Phase I/II clinical trial ofallogeneic natural killer cells (Magicell-NK) | 20240229 |
| 2024/02/16 | The Ministry of Health and Welfare has approved the collaborative autologous Gamma-Delta T cell therapy project by the Company and Changhua Christian Hospital | 20240216 |
| 2024/02/07 | Signing of the sales cooperation agreementfor the new drug OBP-301 in Japan. | 20240207 |
| 2024/01/30 | Announcement of Important Resolutions by the Board of Directors of Our Company | 20240130 |
| 2024/01/11 | Approved the collaborative autologous Gamma-Delta T cell therapy project by the Company and Taichung Tzu Chi Hospital | 20240111 |
